107550-30-1

Basic information

• Product Name: 5-(benzyloxy)-4-hydroxypicolinic acid
• Synonyms: 5-(benzyloxy)-4-hydroxypicolinic acid;3-Benzyloxy-4-pyridone-6-carboxylic acid;5-Benzyloxy-4-pyridone-2-carboxylic acid;O-Benzylcomenamic acid;5-(benzyloxy)-4-oxo-1,4-dihydropyridine-2-carboxylic acid;5-benzyloxy-4-oxo-1h-pyridine-2-carboxylic acid;2-Pyridinecarboxylic acid, 1,4-dihydro-4-oxo-5-(phenylmethoxy)-
• CAS NO: 107550-30-1
• Molecular Formula: C₁₃H₁₁NO₄
• Molecular Weight: 245.23074
• Mol File: 107550-30-1.mol

Chemical Properties

• Boiling Point: 475.6±45.0 °C(Predicted)
• Appearance: /
• Density: 1.37
• Storage Temp.: 2-8°C
• PKA: 0.53±0.20(Predicted)
• CAS DataBase Reference: 5-(benzyloxy)-4-hydroxypicolinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(benzyloxy)-4-hydroxypicolinic acid(107550-30-1)
• EPA Substance Registry System: 5-(benzyloxy)-4-hydroxypicolinic acid(107550-30-1)

Safety Data

• Hazardous Substances Data: 107550-30-1(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
5-(benzyloxy)-4-hydroxypicolinic acid is used as a building block in organic synthesis for the creation of other bioactive compounds. Its unique structure allows for the development of new molecules with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5-(benzyloxy)-4-hydroxypicolinic acid is used as a starting material for the development of new drug molecules. Its potential biological activities make it a valuable candidate for further research and development.
Used in Anti-inflammatory Applications:
5-(benzyloxy)-4-hydroxypicolinic acid is used as an anti-inflammatory agent due to its ability to modulate inflammatory pathways. This property makes it a promising candidate for the treatment of various inflammatory conditions.
Used in Antitumor Applications:
5-(benzyloxy)-4-hydroxypicolinic acid is used as an antitumor agent, exhibiting potential inhibitory effects on tumor growth and progression. Its ability to target specific cellular processes involved in cancer development and spread makes it a valuable compound in oncology research.
Used in Enzyme Inhibition:
5-(benzyloxy)-4-hydroxypicolinic acid is used to inhibit certain enzymes, which can be beneficial in the treatment of various diseases. By targeting specific enzymes, this compound may help regulate biological processes and provide therapeutic benefits.

Upstream product

• 100-44-7 benzyl chloride 
• 1336-21-6 ammonium hydroxide 
• 1219-33-6 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid 
• 15771-06-9 5-benzyloxy-2-hydroxymethyl-4H-pyran-4-one 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 

Downstream Products

• 188011-50-9 5-benzyloxy-4-methoxypyridine-2-carboxylic acid methyl ester 
• 188048-45-5 WS75624 B 
• 1229937-08-9 4,5-bis(benzyloxy)pyridine-2-carbohydrazide 
• 1229937-22-7 (R)-3-(4,5-bis(benzyloxy)pyridin-2-yl)-4-(2,3-dihydroxypropyl)-1H-1,2,4-triazol-5(4H)-one 
• 1229937-09-0 5-(4,5-bis(benzyloxy)pyridin-2-yl)-1,3,4-oxadiazol-2(3H)-one 
• 112334-42-6 benzyl 4,5-bis(benzyloxy)picolinate 
• 107550-31-2 5-(benzyloxy)-1,4-dihydro-4-oxo-2-pyridinecarboxylic acid, ethyl ester 

Relevant articles and documents

Preparation, gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols

A novel series of monocarbam compounds exhibiting promising antibacterial activity against multidrug resistant Gram-negative microorganisms is reported, along with the synthesis of one such molecule MC-1 (1). Also reported are structure-activity relationships associated with the in vitro and in vivo efficacy of 1 and related analogues in addition to the hydrolytic stability of such compounds and possible implications thereof.

MONOCARBAMS

The invention relates to compounds of formula (I): wherein R1, R2, R3, R4, Rs, and R6 as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of formula (I)

The total synthesis of the natural product endothelin converting enzyme (ECE) inhibitor, WS75624 B

The first total synthesis of WS75624 B, 1, an endothelin converting enzyme inhibitor produced in a fermentation broth of Saccharothrix sp. No. 75624 is reported herein. WS75624 B is synthesized in 14 steps from commercially available kojic acid, 2. The synthetic methodology allows for facile substitution at multiple sites on the molecule.

2-oxo-1-[[(substituted sulfonyl)amino]carbonyl]azetidines

Antibacterial activity is exhibited by 2-azetidinones having a 3-acylamino substituent and having an activating group in the 1-position of the formula STR1

1-(substituted phosphorous)-azetidinone antibacterials

Antibacterial activity is exhibited by 2-azetidinones having an acylamino substituent in the 3-position and having an activating group in the 1-position of the formula STR1

3-acylamino-2-oxo-1-azetidinesulfonic acids

Antibacterial activity is exhibited by 2-azetidinones activated in the 1-position with an --SO3 H group and having in the 3-position an acylamino group of the formula STR1